In addition to the abovementioned effect on urolithiasis development, metformin inhibits the progression of autosomal dominant polycystic kidney disease, interfering with cell proliferation and inhibiting cystic fibrosis transmembrane conductance regulator (CFTR) and mTOR signals through AMPK. Here, CFTR is linked to autosomal dominant polycystic kidney disease.